cytomx
therapeutics
announces
treatment
first
patient
phase
expansion
study
probody
drug
conjugate
south
san
francisco
globe
newswire
cytomx
therapeutics
nasdaq
ctmx
biopharmaceutical
company
pioneering
novel
class
investigational
antibody
therapeutics
based
technology
platform
today
announced
treatment
first
patient
phase
expansion
study
probody
drug
conjugate
study
conducted
partnership
abbvie
evaluating
monotherapy
four
cohorts
squamous
cell
lung
cancer
sqnsclc
squamous
head
neck
cancer
sqhnscc
esophageal
cancer
diffuse
large
lymphoma
dlbcl
phase
advancement
previously
undruggable
target
marks
major
milestone
broadening
clinical
pipeline
highlights
progress
continue
make
applying
probody
platform
unique
therapeutic
opportunities
cancer
said
amy
peterson
md
chief
development
officer
cytomx
therapeutics
expansion
cohorts
build
phase
clinical
experience
achieved
meaningful
therapeutic
activity
drug
candidate
setting
stage
phase
exploration
phase
cohort
expansion
study
enroll
approximately
evaluable
patients
cohorts
assess
efficacy
tolerability
mg
kg
administered
every
three
weeks
primary
objective
overall
response
rate
orr
secondary
objectives
evaluating
safety
tolerability
cytomx
anticipates
initial
data
study
late
cytomx
abbvie
collaboration
april
abbvie
cytomx
entered
licensing
agreement
two
companies
probody
drug
conjugate
conjugated
cytotoxic
payload
mmae
also
known
transferrin
receptor
cell
surface
protein
essential
iron
uptake
dividing
cells
highly
expressed
number
solid
hematologic
cancers
attractive
molecular
properties
efficient
delivery
cytotoxic
payloads
tumor
cells
high
potential
target
widely
considered
undruggable
due
presence
dividing
healthy
cells
designed
potentially
create
therapeutic
window
novel
target
agreement
cytomx
responsible
clinical
development
initial
clinical
proof
concept
abbvie
lead
clinical
development
global
commercial
activities
cytomx
eligible
receive
million
development
regulatory
commercial
milestone
payments
pending
achievement
outcomes
addition
cytomx
eligible
receive
profit
share
tiered
royalties
net
product
sales
outside
cytomx
retaining
option
first
quarter
cytomx
earned
million
milestone
payment
abbvie
following
achievement
criteria
dose
escalation
phase
ongoing
phase
clinical
trial
cytomx
therapeutics
cytomx
biopharmaceutical
company
vision
transforming
lives
safer
effective
therapies
developing
novel
class
investigational
antibody
therapeutics
based
technology
platform
treatment
cancer
cytomx
strategic
drug
discovery
development
collaborations
abbvie
amgen
astellas
bristol
myers
squibb
probody
therapeutics
designed
remain
inactive
activated
proteases
tumor
microenvironment
result
probody
therapeutics
intended
bind
selectively
tumors
decrease
binding
healthy
tissue
minimize
toxicity
potentially
create
safer
effective
therapies
leaders
field
innovative
technology
designed
turn
previously
undruggable
targets
druggable
targets
enable
effective
combination
therapies
cytomx
partners
comprised
leading
biotechnology
pharmaceutical
companies
developed
robust
pipeline
potential
therapeutic
candidates
novel
difficult
drug
targets
potential
immunotherapeutic
candidates
clinically
validated
targets
cytomx
clinical
stage
pipeline
includes
product
candidates
previously
undruggable
targets
including
probody
drug
conjugate
wholly
owned
cytomx
probody
drug
conjugate
partnered
abbvie
among
cancer
targets
considered
inaccessible
conventional
antibody
drug
conjugates
due
presence
many
healthy
tissues
cytomx
clinical
stage
pipeline
also
includes
cancer
immunotherapeutic
candidates
validated
targets
wholly
owned
probody
therapeutic
probody
therapeutics
partnered
bristol
myers
squibb
additional
information
cytomx
therapeutics
visit
follow
us
linkedin
twitter
cytomx
therapeutics
statements
press
release
includes
statements
statements
involve
known
unknown
risks
uncertainties
important
factors
difficult
predict
may
beyond
control
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
accordingly
rely
statements
including
relating
potential
benefits
safety
efficacy
progress
cytomx
collaborative
partners
product
candidates
potential
benefits
applications
cytomx
probody
platform
technology
cytomx
ability
develop
advance
product
candidates
successfully
complete
clinical
trials
including
ongoing
planned
clinical
trials
risks
uncertainties
contribute
uncertain
nature
statements
include
unproven
nature
cytomx
novel
probody
platform
technology
cytomx
clinical
trial
product
candidates
initial
stages
clinical
development
product
candidates
currently
preclinical
development
process
preclinical
clinical
development
could
potentially
lead
approved
product
long
subject
significant
risks
uncertainties
including
risk
worldwide
pandemic
may
continue
negatively
impact
business
research
clinical
operations
cytomx
partners
including
development
preclinical
drug
candidates
due
delays
disruption
research
activities
development
clinical
drug
candidates
due
delays
disruption
clinical
trials
including
impacts
enrollment
patients
clinical
trials
clinical
trial
disruptions
possibility
results
early
clinical
trials
may
predictive
future
results
possibility
cytomx
clinical
trials
successful
possibility
current
research
may
result
additional
product
candidates
cytomx
dependence
success
cytomx
reliance
third
parties
manufacture
company
product
candidates
possible
regulatory
developments
united
states
foreign
countries
additional
applicable
risks
uncertainties
include
relating
preclinical
research
development
clinical
development
risks
identified
heading
risk
factors
included
cytomx
quarterly
report
form
filed
sec
august
statements
contained
press
release
based
information
currently
available
cytomx
speak
date
made
cytomx
undertake
specifically
disclaims
obligation
update
statements
whether
result
new
information
future
events
changed
circumstances
otherwise
probody
registered
trademark
cytomx
therapeutics
investor
media
contact
stern
investor
relations
stephanie
ascher
